 Pfizer said it will continue to develop the once daily version of its weight loss pill after it saw encouraging data in an early stage trial. The company plans to conduct studies in the second half of the year, evaluating multiple doses of the drug. The pharmaceutical giant in December discontinued a twice daily version of the medication.